MedTrace Logo

Haemofiltration Study : IVOIRE (hIgh VOlume in Intensive Care)

NCT00241228 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2010-10-13

No results posted yet for this study

Summary

Sepsis and septic shock are still important causes of mortality in intensive care medicine. Renal replacement therapy by standard volume haemofiltration is currently used, but a higher-volume haemofiltration may improve the prognosis. The study is a prospective randomized multicenter trial comparing two treatments in patients suffering from septic shock complicated with acute renal failure admitted to ICU. One group will be treated by early high volume haemofiltration (70 ml/kg/h) and the second group by standard volume haemofiltration (35 ml/kg/h). The main outcome will be one-month mortality.

Conditions

  • Shock, Septic
  • Renal Failure, Acute

Interventions

DEVICE

Venovenous haemofiltration (renal replacement therapy)

High Volume ultra filtration (70 ml/kg/h)

DEVICE

Venovenous haemofiltration (renal replacement therapy)

Conventional Volume (35 ml/kg/h)

Sponsors & Collaborators

  • Ministry of Health, France

    collaborator OTHER_GOV

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Olivier JOANNES-BOYAU, Dr · University Hospital, Bordeaux, France

  • Patrick HONORE, Dr · Quuen Astrid Military Hospital, BRUXELLES - Belgium

  • Paul Perez, Dr · University Hospital, Bordeaux, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • Belgium
  • France
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00241228 on ClinicalTrials.gov